Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis

Cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is highly effective in multiple myeloma. We treated patients with light chain amyloidosis (AL) before stem cell transplantation (ASCT), instead of ASCT in ineligible patients or as salvage. Treatment was a combination of bortezomib (1.5 mg/m(2...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Mikhael, Joseph R., Schuster, Steven R., Jimenez-Zepeda, Victor H., Bello, Nancy, Spong, Jacy, Reeder, Craig B., Stewart, A. Keith, Bergsagel, P. Leif, Fonseca, Rafael
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2012
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3557400/
https://ncbi.nlm.nih.gov/pubmed/22331188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-11-390930
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak